Molecular genetics of radiographically defined de novo glioblastoma multiforme
- PMID: 11123721
- DOI: 10.1046/j.0305-1846.2000.00290.x
Molecular genetics of radiographically defined de novo glioblastoma multiforme
Abstract
Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low-grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a long-standing, asymptomatic low-grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high-grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32-87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours. pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these specific genetic pathways promote the rapid development of GBM.
Similar articles
-
Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.Brain Pathol. 2000 Apr;10(2):249-59. doi: 10.1111/j.1750-3639.2000.tb00258.x. Brain Pathol. 2000. PMID: 10764044 Free PMC article.
-
Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.J Neurooncol. 2000 Jun;48(2):89-94. doi: 10.1023/a:1006402614838. J Neurooncol. 2000. PMID: 11083071
-
Genetic profile of gliosarcomas.Am J Pathol. 2000 Feb;156(2):425-32. doi: 10.1016/S0002-9440(10)64746-3. Am J Pathol. 2000. PMID: 10666371 Free PMC article.
-
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.Neuro Oncol. 1999 Apr;1(2):124-37. doi: 10.1093/neuonc/1.2.124. Neuro Oncol. 1999. PMID: 11550308 Free PMC article. Review.
-
Molecular pathogenesis of malignant gliomas.Curr Opin Oncol. 1999 May;11(3):162-7. doi: 10.1097/00001622-199905000-00004. Curr Opin Oncol. 1999. PMID: 10328589 Review.
Cited by
-
Proteases and the biology of glioma invasion.J Neurooncol. 2002 Jan;56(2):149-58. doi: 10.1023/a:1014566604005. J Neurooncol. 2002. PMID: 11995816 Review.
-
Alterations in p53, p21, and MIB-1 labeling index in primary human astrocytomas following radiation therapy.J Neurooncol. 2005 Sep;74(2):151-4. doi: 10.1007/s11060-004-6911-5. J Neurooncol. 2005. PMID: 16193385
-
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.Cancer Invest. 2012 Jan;30(1):48-56. doi: 10.3109/07357907.2011.630050. Cancer Invest. 2012. PMID: 22236189 Free PMC article. Review.
-
Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.Pharmaceuticals (Basel). 2023 May 26;16(6):793. doi: 10.3390/ph16060793. Pharmaceuticals (Basel). 2023. PMID: 37375742 Free PMC article. Review.
-
Familial/inherited cancer syndrome: a focus on the highly consanguineous Arab population.NPJ Genom Med. 2020 Feb 3;5:3. doi: 10.1038/s41525-019-0110-y. eCollection 2020. NPJ Genom Med. 2020. PMID: 32025336 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous